UCB Pharma Limited has updated the SmPC for rozanolixizumab. Details of the change are highlighted here.

UCB Pharma Limited has updated the Summary of Product Characteristics for rozanolixizumab.

The sections of the SmPC where changes have been made are highlighted below with removed text struck-through and new text underlined.

Note

The sections listed on this page only show the sections which have changed. Users of these products should refer to the full, current SmPC for more details.

Some symbols and tables do not render well in this view. Embedded images such as graphs and user instruction diagrams are not checked for changes.